MX2022000845A - Compuestos inhibidores. - Google Patents
Compuestos inhibidores.Info
- Publication number
- MX2022000845A MX2022000845A MX2022000845A MX2022000845A MX2022000845A MX 2022000845 A MX2022000845 A MX 2022000845A MX 2022000845 A MX2022000845 A MX 2022000845A MX 2022000845 A MX2022000845 A MX 2022000845A MX 2022000845 A MX2022000845 A MX 2022000845A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor compounds
- activity
- compounds
- des1
- undesirable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019902614A AU2019902614A0 (en) | 2019-07-24 | Inhibitor compounds | |
| PCT/AU2020/050763 WO2021012018A1 (en) | 2019-07-24 | 2020-07-24 | Inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000845A true MX2022000845A (es) | 2022-04-20 |
Family
ID=74192564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000845A MX2022000845A (es) | 2019-07-24 | 2020-07-24 | Compuestos inhibidores. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12448371B2 (https=) |
| EP (1) | EP4003986A4 (https=) |
| JP (2) | JP2022542140A (https=) |
| KR (1) | KR20220041843A (https=) |
| CN (1) | CN114450281B (https=) |
| AU (1) | AU2020316243A1 (https=) |
| BR (1) | BR112022001270A2 (https=) |
| CA (1) | CA3144506A1 (https=) |
| IL (1) | IL290087B1 (https=) |
| MX (1) | MX2022000845A (https=) |
| WO (1) | WO2021012018A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202213792D0 (en) * | 2022-09-21 | 2022-11-02 | Benevolentai Bio Ltd | New compounds and method |
| US11912675B1 (en) | 2023-10-11 | 2024-02-27 | King Faisal University | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound |
| US11919872B1 (en) | 2023-10-11 | 2024-03-05 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
| US11891366B1 (en) | 2023-10-12 | 2024-02-06 | King Faisal University | 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
| US11999706B1 (en) | 2023-10-13 | 2024-06-04 | King Faisal University | 4-chloro-N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2923661A (en) | 1957-03-22 | 1960-02-02 | Irwin Neisler And Co | N-[2-(1-phenyl-propyl)]-2, 2, 2-trichloroethylidenimine |
| US5684018A (en) | 1994-12-13 | 1997-11-04 | Merck & Co., Inc. | Acyloxyisopropyl carbamates as prodrugs for amine drugs |
| FI982268L (fi) | 1998-10-20 | 2000-04-21 | Tomi Jaervinen | Ei-steroidaalisten anti-inflammatoristen karboksyylihappojen uudet pro drugit, niiden valmistus ja käyttö |
| EP2162427A1 (en) * | 2007-05-22 | 2010-03-17 | Novartis Ag | Benzamides useful as s1p receptor modulators |
| WO2012164103A2 (en) | 2011-06-03 | 2012-12-06 | Universität Zürich | Blockers of the nogo-a s1pr pathway for the treatment of diseases characterized by neuronal damage and lack of subsequent repair |
| US20170165230A1 (en) * | 2014-04-09 | 2017-06-15 | Christopher Rudd | Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity |
| AU2015281799B2 (en) * | 2014-06-26 | 2019-11-28 | Central Adelaide Local Health Network Incorporated | Enzyme interacting agents |
| US11135207B2 (en) * | 2016-12-13 | 2021-10-05 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
| CN108079303A (zh) | 2017-12-14 | 2018-05-29 | 广东药科大学 | 鞘氨醇激酶抑制剂在制备治疗肝纤维化药物中的应用 |
-
2020
- 2020-07-24 CA CA3144506A patent/CA3144506A1/en active Pending
- 2020-07-24 AU AU2020316243A patent/AU2020316243A1/en active Pending
- 2020-07-24 WO PCT/AU2020/050763 patent/WO2021012018A1/en not_active Ceased
- 2020-07-24 BR BR112022001270A patent/BR112022001270A2/pt unknown
- 2020-07-24 MX MX2022000845A patent/MX2022000845A/es unknown
- 2020-07-24 US US17/629,218 patent/US12448371B2/en active Active
- 2020-07-24 CN CN202080066385.5A patent/CN114450281B/zh active Active
- 2020-07-24 JP JP2022505207A patent/JP2022542140A/ja active Pending
- 2020-07-24 KR KR1020227003262A patent/KR20220041843A/ko active Pending
- 2020-07-24 EP EP20843975.2A patent/EP4003986A4/en active Pending
-
2022
- 2022-01-24 IL IL290087A patent/IL290087B1/en unknown
-
2025
- 2025-06-16 JP JP2025100363A patent/JP2025134819A/ja active Pending
- 2025-09-08 US US19/322,461 patent/US20260001870A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020316243A1 (en) | 2022-03-03 |
| BR112022001270A2 (pt) | 2022-06-14 |
| CN114450281A (zh) | 2022-05-06 |
| EP4003986A1 (en) | 2022-06-01 |
| IL290087B1 (en) | 2026-01-01 |
| EP4003986A4 (en) | 2023-03-01 |
| US20220274970A1 (en) | 2022-09-01 |
| JP2025134819A (ja) | 2025-09-17 |
| KR20220041843A (ko) | 2022-04-01 |
| WO2021012018A1 (en) | 2021-01-28 |
| US20260001870A1 (en) | 2026-01-01 |
| US12448371B2 (en) | 2025-10-21 |
| IL290087A (en) | 2022-03-01 |
| JP2022542140A (ja) | 2022-09-29 |
| CN114450281B (zh) | 2024-08-16 |
| CA3144506A1 (en) | 2021-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022000845A (es) | Compuestos inhibidores. | |
| ECSP20005581A (es) | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp | |
| BR112022001393A2 (pt) | Forma cristalina do inibidor de atr e seu uso | |
| ECSP19044159A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| CL2018000119A1 (es) | Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret. | |
| EA201790398A1 (ru) | Способы лечения заболевания печени | |
| CO2018013293A2 (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
| MX385122B (es) | Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica. | |
| CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| EA201790660A1 (ru) | Ингибитор киназ | |
| EA201991556A1 (ru) | Ингибиторы фосфодиэстеразы и способы лечения микробной инфекции | |
| MX374633B (es) | Combinaciones terapeuticas para usarse en el tratamiento de tumores. | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| MX379286B (es) | INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe). | |
| CL2018000523A1 (es) | Método para la inhibición de la absorción de lípidos y/o la promoción de excreción de lípidos usando d-psicosa | |
| NI201400109A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| EA201691555A1 (ru) | Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени | |
| AR122380A1 (es) | Uso de inhibidores de sglt-2 para la prevención y/o tratamiento de enfermedades cardíacas en felinos | |
| MX387658B (es) | Métodos para tratar y/o prevenir queratosis actínica. | |
| EP4003299A4 (en) | Treatment of skin disorders with topical tapinarof-egfr inhibitor compositions | |
| MX2017012123A (es) | Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer. | |
| AR087902A1 (es) | COMPOSICIONES Y METODOS PARA TRATAR EL CANCER USANDO EL INHIBIDOR DE PI3Kb Y EL INHIBIDOR DE LA VIA DE MAPK, INCLUIDOS LOS INHIBIDORES DE MEK Y RAF | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| CO2023004447A2 (es) | Composiciones y métodos para el tratamiento de distrofias musculares |